| __timestamp | BioMarin Pharmaceutical Inc. | Celldex Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 129764000 | 101881000 |
| Thursday, January 1, 2015 | 152008000 | 4011000 |
| Friday, January 1, 2016 | 209620000 | 102026000 |
| Sunday, January 1, 2017 | 241786000 | 96171000 |
| Monday, January 1, 2018 | 315264000 | 66449000 |
| Tuesday, January 1, 2019 | 359466000 | 42672000 |
| Wednesday, January 1, 2020 | 524272000 | 42534000 |
| Friday, January 1, 2021 | 470515000 | 3068000 |
| Saturday, January 1, 2022 | 483669000 | 1400000 |
| Sunday, January 1, 2023 | 577065000 | 3008000 |
| Monday, January 1, 2024 | 580235000 |
In pursuit of knowledge
In the competitive landscape of biotechnology, understanding cost structures is crucial. BioMarin Pharmaceutical Inc. and Celldex Therapeutics, Inc. have shown contrasting trends in their cost of revenue from 2014 to 2023. BioMarin's cost of revenue has surged by approximately 345%, reflecting its expanding operations and increased production capabilities. In contrast, Celldex's costs have fluctuated, peaking in 2016 and then declining by about 97% by 2023, indicating strategic shifts or operational scaling back.
These insights provide a window into the strategic decisions and market dynamics influencing these biotech giants over the past decade.
Bristol-Myers Squibb Company vs BioMarin Pharmaceutical Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Zoetis Inc. vs BioMarin Pharmaceutical Inc.
Analyzing Cost of Revenue: GSK plc and BioMarin Pharmaceutical Inc.
Comparing Cost of Revenue Efficiency: GSK plc vs Celldex Therapeutics, Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Celldex Therapeutics, Inc.
Cost Insights: Breaking Down Viatris Inc. and BioMarin Pharmaceutical Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Veracyte, Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Cost Insights: Breaking Down BioMarin Pharmaceutical Inc. and Evotec SE's Expenses
Sarepta Therapeutics, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Walgreens Boots Alliance, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Bausch Health Companies Inc. and Celldex Therapeutics, Inc.